Over a mean follow-up of 4.4 ± 2.2 years, 137 patients (24.5%) experienced major adverse cardiovascular events, with FFR-CT use associated with a favorable trend toward risk reduction and a significant decrease in all-cause mortality [ 54 ].
1
—
—
Over a mean follow-up of 4.4 ± 2.2 years, 137 patients (24.5%) experienced major adverse cardiovascular events, with FFR-CT use associated with a favorable trend toward risk reduction and a significant decrease in all-cause mortality [ 54 ].